CION Ameerpet
Genetics · Reviewed by CION Oncologists · NABH Accredited
Surveillance With Lynch Syndrome — What It Actually Involves
Everywhere else on this site you will read that endometrial cancer is not screened for, because no test has been shown to help women at ordinary risk. Lynch syndrome is the exception. Here, surveillance is recommended, it is organised, and for the bowel in particular it is one of the more clearly effective things in preventive medicine. What surprises most people is how much it varies between carriers: the schedule depends on which of the mismatch repair genes is involved, because the risks attached to them differ considerably. This page explains what surveillance covers, why it is individualised, and what to expect.
- The exception to the screening rule — here, surveillance is recommended
- Colonoscopy has the strongest evidence — it prevents cancers, not just finds them
- The gene sets the schedule — MLH1 and MSH2 differ from PMS2 substantially
- Bleeding still matters most — surveillance does not replace reporting symptoms
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What Surveillance Covers
Intervals and starting ages are set by your genetics team from your gene and your family history. This page describes what each element is for rather than prescribing a schedule, because a generic schedule would be wrong for a good proportion of carriers.
| Element | What it is for |
|---|---|
| Colonoscopy | The cornerstone, and the part with the strongest evidence behind it. Because bowel cancers arise from polyps that can be removed during the procedure, colonoscopy prevents cancers rather than merely detecting them. Regular colonoscopy in Lynch syndrome is associated with reduced bowel cancer deaths. See the endometrial and bowel link. |
| Endometrial surveillance | May be offered — typically ultrasound with or without endometrial sampling from a starting age set by your team. Honest caveat: the evidence that it reduces deaths is considerably weaker than for colonoscopy, because endometrial cancer usually announces itself through bleeding and is caught that way. See endometrial biopsy. |
| Prompt assessment of any bleeding | The most valuable single measure for the uterus, and it is not a test at all. Any abnormal bleeding — and any bleeding at all after menopause — should be assessed promptly rather than waiting for the next scheduled appointment. |
| Upper gastrointestinal endoscopy | Considered for some carriers, particularly where there is stomach cancer in the family or specific gene involvement. Not routine for everyone, and a decision for your genetics team. |
| Helicobacter pylori testing | Testing and treating this common stomach infection is generally recommended, since it contributes to stomach cancer risk. Straightforward and worth doing. |
| Discussion of risk-reducing surgery | Hysterectomy with removal of tubes and ovaries, once childbearing is complete, is the intervention that most effectively addresses the gynaecological risk. It is a discussion, not a directive. See risk-reducing surgery. |
| Cascade testing for relatives | Part of the plan rather than an afterthought. Each first-degree relative has a one in two chance of carrying the same variant, and those who do can enter surveillance. See testing your family. |
Ask which gene you carry and ask for your plan in writing. Surveillance runs for decades and involves several specialties; a written plan naming the gene, the tests, the intervals and who is responsible for recalling you is what keeps it from quietly lapsing.
Did You Know? Lynch syndrome is not one condition but five, and treating them as one is the commonest error in how it is explained. A woman with an MLH1 or MSH2 variant carries a substantially higher lifetime risk of both bowel and endometrial cancer than a woman with a PMS2 variant, whose risks are considerably lower. MSH6 sits differently again, with a lower bowel risk but a substantial endometrial one. This is why a surveillance schedule copied from a website or from a relative with a different variant can be wrong in either direction — too much for some, too little for others. The gene should be named on your report, and it should drive your plan. Sources: NCCN Clinical Practice Guidelines in Oncology — Genetic/Familial High-Risk Assessment: Colorectal, Endometrial and Gastric; European Hereditary Tumour Group guidelines on Lynch syndrome; Manchester International Consensus Group recommendations.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Why the Gene Matters So Much
The single most useful thing to understand about your own surveillance.
- MLH1 and MSH2 carry the highest risks. Both bowel and endometrial risk are substantially elevated, and surveillance is correspondingly more intensive and starts earlier.
- EPCAM behaves like MSH2. A deletion in EPCAM silences the neighbouring MSH2 gene, so it is managed along similar lines.
- MSH6 carries a lower bowel risk and a substantial endometrial risk. Which changes the emphasis of surveillance rather than simply its intensity — the gynaecological side becomes relatively more important.
- PMS2 carries the lowest risks. Meaningfully lower than the others, and surveillance is generally less intensive and starts later. Being told this is a relief for many carriers and it is accurate.
- Family history modifies all of it. Cancers occurring at unusually young ages in your family can shift a schedule earlier regardless of gene. This is why the plan comes from a genetics team rather than from a table. See genetic counselling.
Want a Surveillance Plan That Fits Your Gene?
Genetics, gynaecology and gastroenterology coordinated, with your plan set out in writing.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Not One Schedule for Everyone
MLH1, MSH2, MSH6 and PMS2 carry different risks. Your plan should name your gene.
Making Surveillance Actually Work
Surveillance runs for decades. The commonest failure is not a missed finding but a lapsed schedule.
Establish who recalls you
The single most practical question. Surveillance involves several departments and the responsibility for calling you back is easy to lose between them — particularly after moving city, changing hospital, or when a doctor retires. Ask explicitly whose list you are on, and keep your own diary as a backstop.
Never wait for the next appointment to report a symptom
Surveillance detects what is present on the day. A symptom arising between appointments deserves assessment when it arises. For the uterus this matters most: any abnormal bleeding, and any bleeding at all after menopause, should be assessed promptly. See bleeding after menopause.
Take the bowel preparation seriously
An unhelpful but important point. A colonoscopy performed on an inadequately prepared bowel can miss small polyps, which defeats the purpose of the whole exercise. If you have struggled with preparation before, say so beforehand — there are alternatives.
Keep your own copies
Your genetic report naming the variant, and a record of each procedure and its findings. Over twenty years across multiple hospitals this becomes genuinely valuable, and it is the thing most often lost.
Do not let family testing drift
Every first-degree relative has a one in two chance of carrying the same variant, and those who do can enter surveillance that demonstrably reduces bowel cancer deaths. This is the highest-value action available to you, and it is the one most often postponed. See testing your family.
Not Sure Whether Your Surveillance Is Right?
Bring your genetic report. A review of whether your plan matches your gene and your family history. The opinion is free.
Living With the Knowledge
A genetic diagnosis is information about probability, not about destiny, and the distinction matters for how you live with it.
- Carrying a variant does not mean you will get cancer. Even for the higher-risk genes, a meaningful proportion of carriers never develop one. Lifetime risk figures describe groups over decades, not what will happen to you.
- Surveillance changes the odds, not just the timing. Colonoscopy removes polyps before they become cancers, so it prevents disease rather than merely finding it earlier. This is a genuinely strong intervention.
- The anxiety is real and is treatable. Many carriers find the period around each appointment difficult. This is common, it is not a failure of coping, and support helps. See coping with a diagnosis.
- Prevention is broader than surveillance. Aspirin is recommended for many carriers on the basis of trial evidence, and weight and activity contribute as they do for everyone. See preventing Lynch cancers.
- Cancers found in Lynch syndrome respond well. Mismatch repair deficient tumours have distinctive characteristics that make particular classes of treatment effective, which is part of why the outlook is often better than the risk figures suggest. See Lynch-related endometrial cancer.
Why Surveillance Belongs in a Coordinated Service
Because it spans three specialties for several decades, and that is exactly where plans quietly lapse.
Lynch counselling built in
One place for the whole pathway
Follow-up you can actually keep
Tumour board for every diagnosis
Named MCh surgical oncologists
Costs explained before you commit
Take The Next Step
Ask Whose List You Are On
The commonest failure in twenty-year surveillance is not a missed finding — it is a lapsed recall.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Lynch Syndrome Surveillance — Frequently Asked Questions
What does surveillance for Lynch syndrome involve?
Regular colonoscopy is the core of it, and the element with the strongest evidence — because bowel cancers arise from polyps that can be removed during the procedure, colonoscopy prevents cancers rather than only detecting them, and regular colonoscopy in Lynch syndrome is associated with fewer bowel cancer deaths. Gynaecological surveillance may be offered, usually ultrasound with or without endometrial sampling. Upper gastrointestinal endoscopy is considered for some carriers, and testing for Helicobacter pylori is generally recommended. Alongside all of it sit two things that are not tests: prompt assessment of any abnormal bleeding, and discussion of risk-reducing surgery once childbearing is complete.
Why is my schedule different from my cousin's?
Almost certainly because of the gene, and possibly because of family history. Lynch syndrome is caused by a variant in one of several mismatch repair genes, and the risks attached to them differ substantially: MLH1 and MSH2 carry the highest risks of bowel and endometrial cancer, MSH6 carries a lower bowel risk with a substantial endometrial risk, and PMS2 carries the lowest risks overall. Surveillance is set accordingly. Cancers occurring at unusually young ages in a family can also shift a schedule earlier. This is why a plan copied from a relative or a website can be wrong in either direction.
Does endometrial surveillance actually prevent cancer?
The honest answer is that the evidence is weaker here than for the bowel, and it is worth knowing that. Colonoscopy prevents bowel cancers by removing polyps; there is no equivalent for the uterus, and no gynaecological surveillance test has been shown to reduce endometrial cancer deaths in the way colonoscopy reduces bowel cancer deaths. Surveillance is still offered by many centres and can detect changes early. But the measure that matters most for the uterus is not a test — it is having any abnormal bleeding assessed promptly rather than waiting for a scheduled appointment.
Should I have a hysterectomy instead of surveillance?
It is a genuine option and one that should be discussed once childbearing is complete, rather than either assumed or dismissed. Removing the uterus, tubes and ovaries addresses the gynaecological risk far more effectively than surveillance does. The considerations against it are real: it is surgery, and removing the ovaries before natural menopause brings on early menopause with consequences for bone and cardiovascular health that need managing. Many women choose it, many choose surveillance, and both are reasonable. The decision should be made with a genetics team and a gynaecological oncologist who know your gene and your circumstances.
What if I move or change hospitals?
This is where surveillance most often breaks down, and it is worth guarding against actively. Before you move, ask for a written summary naming your genetic variant, the surveillance plan, the dates and findings of everything done so far, and a copy of your original genetic report. Ask your new centre explicitly whose list you are on and when your next appointment is due, and keep your own diary as a backstop. Over twenty or thirty years and across several hospitals, the patient who holds their own records is considerably less likely to fall through a gap.
Medical disclaimer: This page provides general information about surveillance in Lynch syndrome, reviewed by a CION oncologist. It is not a substitute for individual genetic counselling or medical advice. Surveillance schedules are individualised according to the specific gene involved, personal history and family history, and should be set by a clinical genetics service. Any abnormal bleeding, and any bleeding after menopause, should be assessed promptly rather than deferred to the next scheduled appointment.